Muriel Quaranta
Overview
Explore the profile of Muriel Quaranta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
424
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Andrieu G, Quaranta M, Leprince C, Hatzoglou A
FASEB J
. 2012 Sep;
26(12):5025-34.
PMID: 22964304
Within the Ras superfamily, Gem is a small GTP-binding protein that plays a role in regulating Ca(2+) channels and cytoskeletal remodeling in interphase cells. Here, we report for the first...
12.
Brezak M, Valette A, Quaranta M, Contour-Galcera M, Jullien D, Lavergne O, et al.
Int J Cancer
. 2008 Dec;
124(6):1449-56.
PMID: 19065668
CDC25 phosphatases are key actors in cyclin-dependent kinases activation whose role is essential at various stages of the cell cycle. CDC25 expression is upregulated in a number of human cancers....
13.
Meunier B, Quaranta M, Daviet L, Hatzoglou A, Leprince C
Eur J Cell Biol
. 2008 Nov;
88(2):91-102.
PMID: 19004523
Amphiphysins are BIN-amphiphysin-RVS (BAR) domain-containing proteins that influence membrane curvature in sites such as T-tubules in muscular cells, endocytic pits in neuronal as well as non-neuronal cells, and possibly cytoplasmic...
14.
Braud E, Goddard M, Kolb S, Brun M, Mondesert O, Quaranta M, et al.
Bioorg Med Chem
. 2008 Sep;
16(19):9040-9.
PMID: 18789703
CDC25 phosphatases are considered as attractive targets for anti-cancer therapy. To date, quinone derivatives are among the most potent inhibitors of CDC25 phosphatase activity. We present in this paper the...
15.
Didier C, Cavelier C, Quaranta M, Demur C, Ducommun B
Eur J Pharmacol
. 2008 Jul;
591(1-3):102-5.
PMID: 18616938
Polo-Kinase 1 (PLK1) is a key cell cycle regulator that is necessary for checkpoint recovery after DNA damage-induced G2 arrest. We have examined the effects of PLK inhibition in Acute...
16.
Cazales M, Quaranta M, Lobjois V, Jullien D, Al Saati T, Delsol G, et al.
Cell Cycle
. 2008 Feb;
7(2):267-8.
PMID: 18256524
No abstract available.
17.
Bugler B, Quaranta M, Aressy B, Brezak M, Prevost G, Ducommun B
Mol Cancer Ther
. 2006 Jul;
5(6):1446-51.
PMID: 16818502
Cell cycle arrest at the G2-M checkpoint is an essential feature of the mechanisms that preserve genomic integrity. CDC25 phosphatases control cell cycle progression by dephosphorylating and activating cyclin-dependent kinase/cyclin...
18.
Brezak M, Quaranta M, Contour-Galcera M, Lavergne O, Mondesert O, Auvray P, et al.
Mol Cancer Ther
. 2005 Sep;
4(9):1378-87.
PMID: 16170030
Cell cycle regulators, such as the CDC25 phosphatases, are potential targets for the development of new anticancer drugs. Here we report the identification and the characterization of BN82685, a quinone-based...
19.
Brun M, Braud E, Angotti D, Mondesert O, Quaranta M, Montes M, et al.
Bioorg Med Chem
. 2005 Jun;
13(16):4871-9.
PMID: 15921913
CDC25 dual-specificity phosphatases are essential key regulators of eukaryotic cell cycle progression and the CDC25A and B isoforms are over-expressed in different tumors and related cancer cell lines. CDC25s are...
20.
Mirey G, Chartrain I, Froment C, Quaranta M, Bouche J, Monsarrat B, et al.
Cell Cycle
. 2005 May;
4(6):806-11.
PMID: 15908796
The phosphatase CDC25B is one of the key regulators that control entry into mitosis through the dephosphorylation and subsequent activation of the cyclin-dependent kinases. Here we study the phosphorylation of...